Tarloxotinib bromide NEW
| Price | $143 | $297 | $455 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-30 |
Product Details
| Product Name: Tarloxotinib bromide | CAS No.: 1636180-98-7 |
| Purity: 97.15% | Supply Ability: 10g |
| Release date: 2025/04/30 |
Product Introduction
Bioactivity
| Name | Tarloxotinib bromide |
| Description | Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2. |
| In vitro | Tarloxotinib bromide is metabolized efficiently under hypoxia using a panel of human NSCLC cell lines (rate of TKI release 0.4-2.1 nM/hr/106 cells), a process that is inhibited by oxygen (TKI release <0.002 nM/hr/106 cells). Cellular anti-proliferative and receptor phosphorylation assays demonstrate a 14-80 fold reduction of Tarloxotinib bromide activity relative to TKI. Using PC9 tumors, hyperbaric oxygen breathing suppresse release of TKI from Tarloxotinib bromide by >80% (538 vs 99 nM/kg; p<0.01) compared to air breathing controls[1]. |
| In vivo | Tarloxotinib bromide treatment regresses the WT EGFR NSCLC tumor models H125 and H1648, demonstrating Tarloxotinib bromide provides the necessary therapeutic index to inhibit WT EGFR in vivo[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 33 mg/mL (48.4 mM), Sonication is recommended. |
| Keywords | TH4000 | TH 4000 | Tarloxotinib bromide | Tarloxotinib Bromide | Tarloxotinib | Inhibitor | inhibit | HER2 | HER1 | ErbB-1 | Epidermal growth factor receptor | EGFR/HER2 | EGFR |
| Inhibitors Related | Tannic acid | Osimertinib | Lidocaine Hydrochloride hydrate | Lapatinib | Afatinib Dimaleate | Erlotinib hydrochloride | Erlotinib | Neratinib | Chalcone | Genistein | Khellin | Gefitinib |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $70.00/1kg |
VIP2Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2023-11-20 | |
| $1.00/1kg |
VIP1Y
|
S&Y Biochem Co.,Ltd
|
2024-09-20 | |
| $0.00/10ton |
VIP3Y
|
Hebei ZB Gamay Biological Technology Co.,Ltd
|
2025-05-09 | |
| $143.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-05-02 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY